Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 1/20 | 0.54 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | AHCY | P23526 | 4/20 | 0.47 |
| ▸ | ENPP1 | P22413 | 3/20 | 0.43 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.42 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.42 |
| ▸ | PI4KA | P42356 | 1/20 | 0.42 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.42 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.42 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13714845 | 1.00 | FGFR1 (0.54) | FGFR1SLC22A6CYP3A4AHCYENPP1 | |
| SCHEMBL13714833 | 0.88 | ENPP1 (0.49) | FGFR1SLC22A6CYP3A4AHCYENPP1 | |
| SCHEMBL13714886 | 0.88 | AHCY (0.44) | FGFR1SLC22A6CYP3A4AHCYADORA2A | |
| SCHEMBL3861066 | 0.87 | FDPS (0.46) | FGFR1SLC22A6CYP3A4AHCYENPP1 | |
| SCHEMBL3853182 | 0.86 | HPRT1 (0.44) | FGFR1SLC22A6CYP3A4AHCYENPP1 | |
| SCHEMBL13714781 | 0.86 | HPRT1 (0.44) | FGFR1SLC22A6CYP3A4AHCYENPP1 | |
| SCHEMBL3852153 | 0.84 | AHCY (0.48) | CYP3A4AHCYENPP1ENPP3ADORA2A | |
| SCHEMBL3852186 | 0.84 | SLC22A6 (0.46) | FGFR1SLC22A6CYP3A4AHCYENPP1 | |
| SCHEMBL3852157 | 0.83 | AHCY (0.46) | FGFR1SLC22A6CYP3A4AHCYENPP1 | |
| SCHEMBL3859402 | 0.83 | FGFR1 (0.41) | FGFR1SLC22A6CYP3A4AHCYENPP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7579332-B2 | Nucleobase phosphonate analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-7579332-B2 | Nucleobase phosphonate analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-7579332-B2 | Nucleobase phosphonate analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-20060252729-A1 | Nucleobase phosphonate analogs for antiviral treatment | GILEAD SCIENCES, INC. | 2006-11-09 | — | — | US | disclosed |
| EP-1656387-A2 | NUCLEOBASE PHOSPHONATE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2006-05-17 | — | — | EP | disclosed |
| US-20050059637-A1 | Nucleobase phosphonate analogs for antiviral treatment | GILEAD SCIENCES, INC. | 2005-03-17 | — | — | US | disclosed |
| WO-2005012324-A2 | NUCLEOBASE PHOSPHONATE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252729-A1 | Nucleobase phosphonate analogs for antiviral treatment | TYMP, TK1, NUDT1 | FGFR1 3686/4885SLC22A6 1014/4885CYP3A4 4139/4885 |
| US-20050059637-A1 | Nucleobase phosphonate analogs for antiviral treatment | TYMP, TK1, NUDT1 | FGFR1 3686/4885SLC22A6 1014/4885CYP3A4 4139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.